Diets · Metabolic & Cardiometabolic
magnitude of LDL reduction correlates with cardiovascular disease
In plain terms: Does how much a statin lowers LDL predict how much it cuts heart-attack risk across trials?
Part of: 💊 statins
At the TRIAL level the size of LDL-lowering is a weak surrogate for benefit (R-squared near 0), yet per-mmol meta-analyses and Mendelian randomization still show LDL is causal — so this is a surrogacy gap, not proof LDL is harmless.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
At the trial level, the MAGNITUDE of LDL lowering is a weak predictor of the size of a statin's cardiovascular benefit (Byrne 2022; Liaigre 2025, R^2~0). Norwitz uses this to attack LDL. The honest nuance: this is about dose-response SURROGACY across heterogeneous trials - it does NOT overturn LDL CAUSALITY, which Mendelian randomization and per-mmol CTT analyses support.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Wang 2020 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | 327,037 participants: consistent ~21% RR reduction per mmol/L LDL-C lowering across baseline LDL-C and risk strata. |
| Ference 2017 · JAMA | observational | mixed | high | CETP/HMGCR variant study: CV benefit tracks LDL-lowering but is attenuated when LDL is lowered discordantly with ApoB. |
| Silverman 2016 · JAMA | meta-analysis | supports | high | 49 trials/312,175: across statin AND non-statin LDL-lowering, RR per 1 mmol/L LDL reduction ~0.77, consistent — trial-level dose-response for benefit. |
| Hao 2022 · BMJ | meta-analysis | supports | high | Risk-stratified guideline meta-analysis: adding ezetimibe/PCSK9i yields CV benefit proportional to additional LDL-C reduction. |
| Li 2021 · Eur J Clin Invest | meta-analysis | mixed | high | Umbrella review: many drug-outcome associations weak; anchors that magnitude-benefit links are often overstated |
| Byrne P, et al. 2022 · JAMA Intern Med | meta-analysis | contradicts | moderate | [FT-verified] Byrne2022: weak LDL-MI corr, R2=0 for mortality/stroke; benefit not strongly LDL-mediated at trial level |
| Preiss 2020 · JACC | meta-analysis | supports | high | >25 outcome trials: statins lower major atherosclerotic events ~22% per 1 mmol/L LDL-C, similar across subgroups. |
| Burger 2024 · Atherosclerosis | meta-analysis | supports | high | 60-RCT meta-analysis: CV risk reduction scales with magnitude of LDL-C reduction; effect grows over treatment time. |
| Khan I 2020 · J Am Heart Assoc | meta-analysis | supports | moderate | A time-dependent treatment-benefit model derived from 22 RCTs (statins and non-statins) used 'magnitude of low-density lipoprotein cholesterol reduction' as a core parameter and outperformed CTT-based estimations in predicting benefit across 15 validation trials. |
| Ennezat PV 2023 · J Cardiovasc Pharmacol | meta-analysis | mixed | high | Systematic review/meta-analysis of 60 RCTs (323,950 participants) found that although lipid-lowering therapy reduced all-cause mortality overall (RR 0.92), 'intensive LDL-C percent lowering was not associated with further reductions in all-cause mortality' (RR 1.00) or |
| Ference 2017 · European Heart Journal | observational | supports | high | EAS consensus: genetic, epidemiologic and trial evidence show LDL causally lowers ASCVD proportional to absolute LDL exposure. |
| Marston 2019 · Circulation | meta-analysis | mixed | high | Per-mmol/L benefit differs by lipid lowered: LDL/ApoB-lowering predicts CV benefit whereas triglyceride-lowering does so weakly. |
| Liaigre L, et al. 2025 · Eur Heart J Cardiovasc Pharmacother | meta-analysis | contradicts | moderate | [FT-verified] Liaigre2025 umbrella 20RCTs/194k: trial-level R2 0-0.1 LDL (valid needs>=0.65); lit discrepant; individual surrogacy holds |
| Sabatine 2018 · JAMA Cardiology | meta-analysis | supports | high | ~22% reduction in major vascular events per 1 mmol/L LDL-C lowering; benefit persists even at very low baseline LDL-C. |
| Gencer 2020 · Lancet | meta-analysis | supports | high | In older patients, each 1 mmol/L LDL-C reduction cut major vascular events ~26%, confirming magnitude-driven benefit. |
| CTT Collaboration 2010 · Lancet | meta-analysis | supports | high | 26 RCTs/~170,000: each 1 mmol/L LDL reduction yields ~22% proportional reduction in major vascular events — dose-response holds per-mmol. |
| Ray KK 2023 · Eur Heart J | RCT | supports | moderate | Pooled ORION-9/-10/-11 phase III trial analysis: inclisiran produced a 50.6% (1.37 mmol/L) LDL-C reduction and significantly reduced composite MACE (OR 0.74, 95% CI 0.58-0.94), consistent with the expected direction of the LDL-lowering-to-CV-benefit relationship, though |
| Khan 2022 · Eur J Prev Cardiol | meta-analysis | supports | moderate | Achieving lower (<70) vs higher LDL-C with intensive lipid therapy reduced major events, consistent with magnitude-benefit relation. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.